Haemophilia B - Articles and news items

NovoSeven resolved 96.5% of bleeds in haemophilia A or B sufferers

Industry news / 6 December 2016 / Niamh Louise Marriott, Digital Editor

NovoSeven, a portable room temperature stable recombinant activated factor VIIa, resolved 96.5% of bleeds demonstrating efficacy with haemophilia…

Alprolix approved in Switzerland for the treatment of haemophilia B

Industry news / 31 October 2016 / Niamh Louise Marriott, Digital Content Producer

The Swiss Agency for Therapeutic Products, Swissmedic, has approved Alprolix (eftrenonacog alfa) for the treatment of haemophilia B…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+